Abstract Context Alpha-blockers (ABs) and 5-alpha reductase inhibitors have an established
role in treating male lower urinary tract symptoms (LUTS) attributed to benign prostatic …

Background Benign prostatic hyperplasia (BPH) refers to non‐malignant enlargement of the
prostate gland that may cause bothersome lower urinary tract symptoms (LUTS). Alpha …

Introduction Lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH)
are common in elder men and a number of drugs alone or combined are clinically used for …

Vascular aging leads to structural and functional changes. Iliac arteries (IA) provide blood
flow to lower urinary tract and pelvic ischemia has been reported as an important factor for …

Objective To compare the safety and efficacy of combined therapy using sildenafil and
tamsulosin for management of acute urinary retention (AUR) with tamsulosin alone in …

Methods: Men≥ 45 years of age, with an International Prostate Symptom Score (IPSS)≥ 8
due to BPH-LUTS were included. The patients were randomized into sequence AB (tadalafil …

Placebo medications and sham surgeries have long been thought to be inert treatments.
These groups served as a threshold to which an active treatment should be compared in a …

Objectives: To determine whether tadalafil, a PDE5i, is effective on stent-associated
symptoms. Methods: In this double-blind randomized clinical trial, 80 consecutive male …

Hiperplasia prostática benigna (HPB) é um processo fisiopatológico responsável pela
maioria dos sintomas do trato urinário inferior (STUI). A prevalência da HPB permanece de …

Purpose. We examined the discontinuation rates of tadalafil alone and in combination with a‐
blockers (ABs) for the treatment of male lower urinary tract symptoms (LUTS), with or without …